eClinical Technology and Industy News

Ibex Presents New Data from Multiple Studies Showcasing Accuracy of AI in Prostate, Breast and Gastric Cancer Diagnosis

Studies to Be Presented at the United States and Canadian Academy of Pathology (USCAP) Annual Meeting

  • Brigham and Women’s Hospital and Champalimaud Foundation research shows high accuracy levels of Galen Breast in identifying microinvasive carcinoma of the breast.
  • University of Pittsburgh Medical Center study demonstrates pathologists’ high performance when using Galen Prostate to support primary diagnosis in a live clinical setting.
  • Ohio State University Wexner Medical Center studies show high accuracy for Galen Breast and Galen Gastric in detecting and distinguishing between different types of cancer and in identifying multiple important pathologies.

Excerpt from the Press Release:

BOSTON, March 21, 2024 /PRNewswire/ — Ibex Medical Analytics (Ibex), the leader in AI-powered cancer diagnostics, today announced excellent results across multiple clinical studies conducted with the University of Pittsburgh Medical Center (UPMC), Brigham and Women’s Hospital, Champalimaud Foundation and Ohio State University (OSU). These studies, highlighting the value of Ibex’s AI-powered cancer diagnostics solutions in both diagnostic quality and efficiency, will be presented next week at the United States and Canadian Academy of Pathology (USCAP) Annual Meeting.

Cancer incidence is rising around the world while its diagnosis becomes more complex and nuanced in an era of precision medicine, in which accurate diagnosis is key for enabling personalized and tailored therapies. Increasing demand and diagnostic workloads are compounded by a global shortage of pathologists who still rely heavily on manual work requiring visual analysis of biopsies. Ibex’s Galen™ platform helps overcome these challenges with Artificial Intelligence (AI)-powered workflows and decision-support tools that pathologists use in their everyday practice.

A study conducted at Brigham and Women’s Hospital and Champalimaud Foundation evaluated Galen Breast’s performance in identifying microinvasive carcinoma of the breast in a challenging patient cohort. Microinvasive carcinoma is defined as the focus of invasive breast cancer no larger than 1mm, in which accurate detection has important implications for patient management.

Click the button below to read the entire Press Release:

Continue Reading The Press Release

Discover What Sets TrialStat Apart From Ordinary EDC Platforms

Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?